# Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

> **NCT07318610** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 7050 (estimated)

## Conditions studied

- Peripheral Artery Disease (PAD)

## Interventions

- **DRUG:** REGN7508
- **DRUG:** REGN9933
- **DRUG:** Placebo
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT07318610
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2029-05-05
- **Final completion:** 2029-08-03
- **Target enrollment:** 7050 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318610, "Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07318610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*